Regeneron Pharmaceuticals (REGN) Change in Receivables (2009 - 2026)

Regeneron Pharmaceuticals' Change in Receivables history runs 18 years deep, the most recent figure standing at $838.5 million for Q2 2026.

• In Q2 2026, Change in Receivables rose 2873.4% year-over-year to $838.5 million; the TTM figure through Jun 2026 stood at $968.8 million (up 888.28% YoY), while the FY2025 annual figure was -$498.1 million, down 189.91% from the prior year.
• Change in Receivables for Q2 2026 stood at $838.5 million, up from -$1.2 million in the prior quarter.
• The five-year high for Change in Receivables was $838.5 million in Q2 2026, with the low at -$1.2 billion in Q1 2022.
• The 5-year median for Change in Receivables is $65.8 million (2025), against an average of $29.1 million.
• The sharpest annual moves came in 2022 and 2024: Change in Receivables plunged 2154.03% in 2022, then soared 18200.0% in 2024.
• Regeneron Pharmaceuticals' Change in Receivables stood at -$219.6 million in 2022, then surged by 137.66% to $82.7 million in 2023, then soared by 42.44% to $117.8 million in 2024, then plunged by 56.54% to $51.2 million in 2025, then surged by 1537.7% to $838.5 million in 2026.
• Business Quant data shows REGN's Change in Receivables at $838.5 million in Q2 2026, -$1.2 million in Q1 2026, and $51.2 million in Q4 2025.